Skip to main content
Premium Trial:

Request an Annual Quote

InVivoScribe Strikes Deal With ATCC to Access Cell Lines

NEW YORK (GenomeWeb News) – InVivoScribe Technologies announced yesterday that it has gained access to certain cell lines through a licensing agreement with American Type Culture Collection, a private, non-profit resource center housing biological materials.

Under the agreement, IVS plans to use cell lines that have been characterized and maintained by ATCC to develop and sell non-viable molecular testing reference standards. Because the cell lines are supported by extensive literature, the company touted the cell lines' potential for use in research tests and, pending regulatory approval, new products as well. The agreement ensures that IVS will have access to a continuous supply of homogenous and stable reference standards.

In a statement issued yesterday, IVS Director of Global Marketing Graeme Duncan said the company will introduce the reference standards and controls into assay kits this year and will offer the references, including validation and sensitivity panels, as independent products. Duncan noted that these products will eventually replace controls.

"In due course, IVS will phase out other controls which, while carefully produces and validated internally, do not have the referenced studies provided by ATCC nor the same level of historic, broad, and published proof of utility," Duncan said.

For its part, ATCC has also gained accreditation for its biological material production and testing through the International Organization for Standardization's Guide 34. To meet such standards, biological reference materials must have a confirmed identity as well as well-defined characteristics and an established chain of custody.

IVS said discovering new reference standards and standardizing test controls will support work done at the US Centers of Disease Control and Prevention, the College of American Pathologists, the Association of Molecular Pathology, and other groups doing diagnostic work.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.